0001179110-18-003604.txt : 20180306
0001179110-18-003604.hdr.sgml : 20180306
20180306161417
ACCESSION NUMBER: 0001179110-18-003604
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180302
FILED AS OF DATE: 20180306
DATE AS OF CHANGE: 20180306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: dEsparbes Eric
CENTRAL INDEX KEY: 0001622268
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30319
FILM NUMBER: 18670031
MAIL ADDRESS:
STREET 1: THERAVANCE, INC.
STREET 2: 951 GATEWAY BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Innoviva, Inc.
CENTRAL INDEX KEY: 0001080014
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943265960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 6502389600
MAIL ADDRESS:
STREET 1: 2000 SIERRA POINT PARKWAY
STREET 2: SUITE 500
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: THERAVANCE INC
DATE OF NAME CHANGE: 20020207
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MEDICINE INC
DATE OF NAME CHANGE: 20000302
4
1
edgar.xml
FORM 4 -
X0306
4
2018-03-02
0
0001080014
Innoviva, Inc.
INVA
0001622268
dEsparbes Eric
2000 SIERRA POINT PARKWAY
SUITE 500
BRISBANE
CA
94005
0
1
0
0
Interim PEO, SVP and CFO
Common Stock
2018-03-02
4
A
0
93056
0
A
384866
D
Includes 31,018 shares of common stock granted pursuant to a time-based restricted stock award (RSA). Twenty-five percent of the shares subject to the RSA shall vest on February 20, 2019, and 6.25% of the shares subject to the RSA shall vest quarterly thereafter on the Issuer's standard vesting dates until February 20, 2022, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Includes shares of common stock granted pursuant to a performance-based restricted stock award (PSA). The shares vest pursuant to the PSA over a three-year period upon, and subject to a formula related to, the Issuer's achievement of certain levels of relative total shareholder return (TSR). The "target" number of shares that may vest is 31,019, but the actual number of shares that may vest will range from 0 to 62,038 shares based on the Issuer's relative TSR over the performance period. Subject to achievement of the performance-based vesting conditions, the shares eligible to vest based on achievement will vest on February 20, 2021 provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
Eric d'Esparbes
2018-03-06